Biodesix, Inc. has published the largest lung‑nodule biomarker validation study ever conducted, a milestone for its Nodify CDT blood‑based test. The study appeared in the February 2026 issue of Future Oncology and confirms the test’s high specificity across a broad range of nodule sizes and risk profiles.
The retrospective pooled analysis, titled “Validation of a blood‑based autoantibody test to assess lung cancer risk in 4‑30 mm pulmonary nodules: a retrospective pooled analysis of four cohort studies,” evaluated more than 1,100 patients with non‑calcified nodules ranging from 4 to 30 mm. The Nodify CDT test achieved a specificity of 91‑97% regardless of nodule size or baseline risk factors, and the analysis incorporated data from four independent cohorts drawn from 48 U.S. clinical practices, including the CLARIFY study (NCT06728319).
The consistent performance across diverse real‑world settings strengthens the test’s clinical credibility and supports Biodesix’s strategy to expand primary‑care adoption of its lung‑nodule risk‑assessment platform. The data are expected to aid payer coverage discussions, accelerate market penetration, and underpin the company’s broader growth narrative in the primary‑care‑driven diagnostics space.
Scott Hutton, CEO and President, said, “This comprehensive validation study supports our continued commercial expansion of the Nodify CDT test and reinforces its clinical utility in addressing the substantial market opportunity and system‑wide gaps in patient care that are presented by lung nodule management.” He added, “The demonstrated consistency of Nodify CDT tests, across real‑world practice settings, further strengthens the company’s offering with healthcare providers, payers, and clinical guideline committees.” Dr. James Jett, Co‑Chief Medical Officer, noted, “Most small nodules are benign and clinicians must balance patient care decisions … whether to ‘watch and wait’ with imaging surveillance or, instead, to expedite intervention based on the limited insights provided by the CT scan.” Dr. Luke Yuhico, pulmonologist, observed that the test “detected lung cancer with minimal false positives for nodules 4‑30 mm in size” and assists in clinical decision‑making.
Biodesix’s financial performance in the most recent quarter underscores the commercial momentum behind the Nodify platform. Q4 2025 revenue reached $28.8 million, a 41% year‑over‑year increase, and full‑year 2025 revenue totaled $88.5 million, up 24% YoY. Gross margin in Q4 2025 was 83%, and the company reported positive Adjusted EBITDA for the first time. For FY 2026, Biodesix has guided revenue of $106‑112 million, reflecting continued confidence in the Nodify pipeline and the broader diagnostics strategy.
With this validation, Biodesix remains the only company offering a dual‑test blood‑based solution—Nodify CDT and Nodify XL2—for early lung‑cancer risk assessment. The study’s robust evidence base positions the company to secure payer coverage, expand primary‑care adoption, and accelerate its growth trajectory in a market that continues to seek reliable, non‑invasive tools for lung‑nodule management.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.